The metaphor of a seed pregnant with
possibilities for the growth and development of a new plant is not inappropriate for this provision of a guiding aim.
An integrated part of our Advanced Studies program, our Specialized Study courses and mentorships provide opportunities for dedicated teachers to awaken to new
possibilities for their growth and development as practitioners and teachers of Yoga.
Not exact matches
Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements
and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business
and execute our
growth strategy, including the timing, execution,
and profitability of new
and maturing programs; 2) our ability to perform our obligations under our new
and maturing commercial, business aircraft,
and military
development programs,
and the related recurring production; 3) our ability to accurately estimate
and manage performance, cost,
and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures
and the potential
for additional forward losses on new
and maturing programs; 5) our ability to accommodate,
and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand
and build rates of changing customer preferences
for business aircraft, including the effect of global economic conditions on the business aircraft market
and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries
and markets in which we operate in the U.S.
and globally
and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success
and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals
for the consummation of our announced acquisition of Asco,
and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing
and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing
and Airbus,
and other customers,
and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's
and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand
for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets
and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price
for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers
and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws
and U.S.
and foreign anti-bribery laws such as the Foreign Corrupt Practices Act
and the United Kingdom Bribery Act,
and environmental laws
and agency regulations, both in the U.S.
and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts
and Jobs Act (the «TCJA») that was enacted on December 22, 2017,
and changes to the interpretations of or guidance related thereto,
and the Company's ability to accurately calculate
and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost
and availability of raw materials
and purchased components; 23) our ability to recruit
and retain a critical mass of highly - skilled employees
and our relationships with the unions representing many of our employees; 24) spending by the U.S.
and other governments on defense; 25) the
possibility that our cash flows
and our credit facility may not be adequate
for our additional capital needs or
for payment of interest on,
and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims,
and regulatory actions; 30) exposure to potential product liability
and warranty claims; 31) our ability to effectively assess, manage
and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business
and generate synergies
and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships
and other business disruptions
for ourselves
and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws,
and domestic
and foreign government policies;
and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
These risks
and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain
growth in revenues
for its antiviral
and other programs; the risk that private
and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement
for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy
and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks
and rebates due to ongoing contracts
and future negotiations with commercial
and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments
and geographic regions
and decreases in treatment duration; availability of funding
for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal
and state grant cycles which may not mirror patient demand
and may cause fluctuations in Gilead's earnings; market share
and price erosion caused by the introduction of generic versions of Viread
and Truvada, an uncertain global macroeconomic environment;
and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the
possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers
and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop
and commercialize cell therapies utilizing the zinc finger nuclease technology platform
and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications
for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all,
for new
and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians
and patients may not see advantages of these products over other therapies
and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology
and inflammation / respiratory programs; safety
and efficacy data from clinical studies may not warrant further
development of Gilead's product candidates, including GS - 9620
and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues
and pre-tax earnings;
and other risks identified from time to time in Gilead's reports filed with the U.S. Securities
and Exchange Commission (the SEC).
K12 will provide comprehensive wraparound services targeted to individual student needs
and for the benefit of the school community:
development of strong community within the virtual academy; access to the best
and most current virtual instruction curriculum, assessment
and instruction based on solid research; customizing each student's education to their own individual learning plan; academic success at the school
and individual student levels resulting from teachers» instruction
and constant monitoring of student
growth and achievement with interventions as needed; national
and local parent trainings
and networking; frequent (i.e., every two to three week) teacher / parent communication through emails
and scheduled meetings; establishment of unique settings
for students
and parents to interact; connecting students on a regular basis with students across the United States in similar virtual academies
and across the world through networking
and K12 national competitions (e.g., art contest
and spelling bees)
and International Clubs; access to the entire K12 suite of services
and instructional curriculum (currently including K12, Aventa, A +,
and powerspeak12) to include world languages, credit recovery courses, remedial courses,
and AP courses; participation in a national advanced learners programs; a comprehensive Title I program that will provide additional services
for students; school led trips,
for example, visits to colleges, grade level specific trips such as student summer trips overseas, etc.; School prom; school graduation ceremonies; national college guidance through a network of K12 counselors; school community service opportunities; student developed student body council; school extracurricular activities:
possibilities would include the
development of a golf club, chess club, bowling club.
It is also essential, I feel, to highlight the
possibility of professional
development and growth, should you be accepted
for an internship.
It is not uncommon
for people to change their industry as this could be a result of dissatisfaction with the current work profile, desire to try out in a different profile
for better career
development and income generation
possibilities, or the lack of opportunities
for growth in the current industry.
Gain a dynamic
and challenging role in the area of Technical Surveillance Countermeasures (TSCM)
and / or TEMPEST, electronics, communications,
and technical security that will be the best opportunity
for further
development of my abilities, skills
and knowledge in an established firm with long term career
growth possibilities.
By working with me you will receive inspiration to awaken to the
possibilities for growth in your own experience, help in identifying your strengths to carry you forward on your path to your highest potential
and the
development of your deepest spirituality, as well as guidance
and direction in creating change in your life.